Single User License
INR 170925
Site License
INR 341850
Corporate User License
INR 512775

Service Tax Additional

select a format
Price

Single User License
USD 2500
Site License
USD 5000
Corporate User License
USD 7500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Prostate Cancer-Pipeline Review, H1 2015

Prostate Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Prostate Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Prostate Cancer-Pipeline Review, H1 2015', provides an overview of the Prostate Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prostate Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Prostate Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Prostate Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Prostate Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Prostate Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 11

Prostate Cancer Overview 12

Therapeutics Development 13

Prostate Cancer-Therapeutics under Development by Companies 15

Prostate Cancer-Therapeutics under Investigation by Universities/Institutes 36

Prostate Cancer-Pipeline Products Glance 42

Prostate Cancer-Products under Development by Companies 46

Prostate Cancer-Products under Investigation by Universities/Institutes 74

Prostate Cancer-Companies Involved in Therapeutics Development 80

Prostate Cancer-Therapeutics Assessment 311

Drug Profiles 349

Prostate Cancer-Recent Pipeline Updates 1053

Prostate Cancer-Dormant Projects 1350

Prostate Cancer-Discontinued Products 1386

Prostate Cancer-Product Development Milestones 1394

Appendix 1403

List of Tables

Number of Products under Development for Prostate Cancer, H1 2015 64

Number of Products under Development for Prostate Cancer-Comparative Analysis, H1 2015 65

Number of Products under Development by Companies, H1 2015 67

Number of Products under Development by Companies, H1 2015 (Contd..1) 68

Number of Products under Development by Companies, H1 2015 (Contd..2) 69

Number of Products under Development by Companies, H1 2015 (Contd..3) 70

Number of Products under Development by Companies, H1 2015 (Contd..4) 71

Number of Products under Development by Companies, H1 2015 (Contd..5) 72

Number of Products under Development by Companies, H1 2015 (Contd..6) 73

Number of Products under Development by Companies, H1 2015 (Contd..7) 74

Number of Products under Development by Companies, H1 2015 (Contd..8) 75

Number of Products under Development by Companies, H1 2015 (Contd..9) 76

Number of Products under Development by Companies, H1 2015 (Contd..10) 77

Number of Products under Development by Companies, H1 2015 (Contd..11) 78

Number of Products under Development by Companies, H1 2015 (Contd..12) 79

Number of Products under Development by Companies, H1 2015 (Contd..13) 80

Number of Products under Development by Companies, H1 2015 (Contd..14) 81

Number of Products under Development by Companies, H1 2015 (Contd..15) 82

Number of Products under Development by Companies, H1 2015 (Contd..16) 83

Number of Products under Development by Companies, H1 2015 (Contd..17) 84

Number of Products under Development by Companies, H1 2015 (Contd..18) 85

Number of Products under Development by Companies, H1 2015 (Contd..19) 86

Number of Products under Investigation by Universities/Institutes, H1 2015 88

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 89

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 90

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 91

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 92

Comparative Analysis by Late Stage Development, H1 2015 93

Comparative Analysis by Clinical Stage Development, H1 2015 94

Comparative Analysis by Early Stage Development, H1 2015 95

Comparative Analysis by Unknown Stage Development, H1 2015 96

Products under Development by Companies, H1 2015 97

Products under Development by Companies, H1 2015 (Contd..1) 98

Products under Development by Companies, H1 2015 (Contd..2) 99

Products under Development by Companies, H1 2015 (Contd..3) 100

Products under Development by Companies, H1 2015 (Contd..4) 101

Products under Development by Companies, H1 2015 (Contd..5) 102

Products under Development by Companies, H1 2015 (Contd..6) 103

Products under Development by Companies, H1 2015 (Contd..7) 104

Products under Development by Companies, H1 2015 (Contd..8) 105

Products under Development by Companies, H1 2015 (Contd..9) 106

Products under Development by Companies, H1 2015 (Contd..10) 107

Products under Development by Companies, H1 2015 (Contd..11) 108

Products under Development by Companies, H1 2015 (Contd..12) 109

Products under Development by Companies, H1 2015 (Contd..13) 110

Products under Development by Companies, H1 2015 (Contd..14) 111

Products under Development by Companies, H1 2015 (Contd..15) 112

Products under Development by Companies, H1 2015 (Contd..16) 113

Products under Development by Companies, H1 2015 (Contd..17) 114

Products under Development by Companies, H1 2015 (Contd..18) 115

Products under Development by Companies, H1 2015 (Contd..19) 116

Products under Development by Companies, H1 2015 (Contd..20) 117

Products under Development by Companies, H1 2015 (Contd..21) 118

Products under Development by Companies, H1 2015 (Contd..22) 119

Products under Development by Companies, H1 2015 (Contd..23) 120

Products under Development by Companies, H1 2015 (Contd..24) 121

Products under Development by Companies, H1 2015 (Contd..25) 122

Products under Development by Companies, H1 2015 (Contd..26) 123

Products under Development by Companies, H1 2015 (Contd..27) 124

Products under Investigation by Universities/Institutes, H1 2015 125

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 126

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 127

Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 128

Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 129

Products under Investigation by Universities/Institutes, H1 2015 (Contd..5) 130

Prostate Cancer-Pipeline by 4SC AG, H1 2015 131

Prostate Cancer-Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 132

Prostate Cancer-Pipeline by AB Science, H1 2015 133

Prostate Cancer-Pipeline by AbbVie Inc., H1 2015 134

Prostate Cancer-Pipeline by Acino Pharma AG, H1 2015 135

Prostate Cancer-Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 136

Prostate Cancer-Pipeline by Adamis Pharmaceuticals Corporation, H1 2015 137

Prostate Cancer-Pipeline by ADC Therapeutics Sarl, H1 2015 138

Prostate Cancer-Pipeline by Addex Therapeutics Ltd, H1 2015 139

Prostate Cancer-Pipeline by Aduro BioTech, Inc., H1 2015 140

Prostate Cancer-Pipeline by Advanced Cancer Therapeutics, H1 2015 141

Prostate Cancer-Pipeline by Advantagene, Inc., H1 2015 142

Prostate Cancer-Pipeline by Advaxis, Inc., H1 2015 143

Prostate Cancer-Pipeline by Aeterna Zentaris Inc., H1 2015 144

Prostate Cancer-Pipeline by Aileron Therapeutics, Inc., H1 2015 145

Prostate Cancer-Pipeline by Akshaya Bio Inc., H1 2015 146

Prostate Cancer-Pipeline by Alchemia Limited, H1 2015 147

Prostate Cancer-Pipeline by Alethia Biotherapeutics Inc., H1 2015 148

Prostate Cancer-Pipeline by Almac Discovery Limited, H1 2015 149

Prostate Cancer-Pipeline by Ambrx, Inc., H1 2015 150

Prostate Cancer-Pipeline by Amgen Inc., H1 2015 151

Prostate Cancer-Pipeline by Amorfix Life Sciences Ltd., H1 2015 152

Prostate Cancer-Pipeline by Anavex Life Sciences Corp., H1 2015 153

Prostate Cancer-Pipeline by AndroScience Corporation, H1 2015 154

Prostate Cancer-Pipeline by Angion Biomedica Corp., H1 2015 155

Prostate Cancer-Pipeline by AntiCancer, Inc., H1 2015 156

Prostate Cancer-Pipeline by Antigen Express, Inc., H1 2015 157

Prostate Cancer-Pipeline by Antisense Therapeutics Limited, H1 2015 158

Prostate Cancer-Pipeline by Aphios Corporation, H1 2015 159

Prostate Cancer-Pipeline by APIM Therapeutics AS, H1 2015 160

Prostate Cancer-Pipeline by Aptose Biosciences Inc., H1 2015 161

Prostate Cancer-Pipeline by Armour Therapeutics Inc., H1 2015 162

Prostate Cancer-Pipeline by Arno Therapeutics, Inc., H1 2015 163

Prostate Cancer-Pipeline by ArQule, Inc., H1 2015 164

Prostate Cancer-Pipeline by Arrien Pharmaceuticals, LLC, H1 2015 165

Prostate Cancer-Pipeline by Arrowhead Research Corporation, H1 2015 166

Prostate Cancer-Pipeline by Ascenta Therapeutics, Inc., H1 2015 167

Prostate Cancer-Pipeline by Astellas Pharma Inc., H1 2015 168

Prostate Cancer-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 169

Prostate Cancer-Pipeline by AstraZeneca Plc, H1 2015 170

Prostate Cancer-Pipeline by ATLAB Pharma SAS, H1 2015 171

Prostate Cancer-Pipeline by Avipep Pty Ltd, H1 2015 172

Prostate Cancer-Pipeline by Axelar AB, H1 2015 173

Prostate Cancer-Pipeline by Azaya Therapeutics Incorporated, H1 2015 174

Prostate Cancer-Pipeline by Bavarian Nordic A/S, H1 2015 175

Prostate Cancer-Pipeline by Bayer AG, H1 2015 176

Prostate Cancer-Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 177

Prostate Cancer-Pipeline by Beta Pharma, Inc., H1 2015 178

Prostate Cancer-Pipeline by BHR Pharma, LLC, H1 2015 179

Prostate Cancer-Pipeline by BIND Therapeutics, Inc., H1 2015 180

Prostate Cancer-Pipeline by Bio-Cancer Treatment International Limited, H1 2015 181

Prostate Cancer-Pipeline by Bio-Path Holdings, Inc., H1 2015 182

Prostate Cancer-Pipeline by BioMarin Pharmaceutical Inc., H1 2015 183

Prostate Cancer-Pipeline by Bionature E.A. Ltd., H1 2015 184

Prostate Cancer-Pipeline by Bionomics Limited, H1 2015 185

Prostate Cancer-Pipeline by Biotest AG, H1 2015 186

Prostate Cancer-Pipeline by Biscayne Pharmaceuticals, Inc., H1 2015 187

Prostate Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2015 188

Prostate Cancer-Pipeline by Bristol-Myers Squibb Company, H1 2015 189

Prostate Cancer-Pipeline by Camurus AB, H1 2015 190

Prostate Cancer-Pipeline by Celgene Corporation, H1 2015 191

Prostate Cancer-Pipeline by CellCentric Ltd, H1 2015 192

Prostate Cancer-Pipeline by Celldex Therapeutics, Inc., H1 2015 193

Prostate Cancer-Pipeline by Cellectar Biosciences, Inc., H1 2015 194

Prostate Cancer-Pipeline by Champions Oncology, Inc., H1 2015 195

Prostate Cancer-Pipeline by Cimab S.A., H1 2015 196

Prostate Cancer-Pipeline by Colby Pharmaceutical Company, H1 2015 197

Prostate Cancer-Pipeline by Cold Genesys, Inc., H1 2015 198

Prostate Cancer-Pipeline by Corcept Therapeutics Incorporated, H1 2015 199

Prostate Cancer-Pipeline by Crescendo Biologics Limited, H1 2015 200

Prostate Cancer-Pipeline by CureTech Ltd., H1 2015 201

Prostate Cancer-Pipeline by CureVac GmbH, H1 2015 202

Prostate Cancer-Pipeline by CytoVac A/S, H1 2015 203

Prostate Cancer-Pipeline by CZ BioMed Corp, H1 2015 204

Prostate Cancer-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 205

Prostate Cancer-Pipeline by DEKK-TEC, Inc., H1 2015 206

Prostate Cancer-Pipeline by DexTech Medical AB, H1 2015 207

Prostate Cancer-Pipeline by DiaMedica Inc., H1 2015 208

Prostate Cancer-Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2015 209

Prostate Cancer-Pipeline by DormaTarg, Inc., H1 2015 210

Prostate Cancer-Pipeline by Eisai Co., Ltd., H1 2015 211

Prostate Cancer-Pipeline by Eli Lilly and Company, H1 2015 212

Prostate Cancer-Pipeline by Emergent BioSolutions Inc., H1 2015 213

Prostate Cancer-Pipeline by Enceladus Pharmaceuticals BV, H1 2015 214

Prostate Cancer-Pipeline by Endo Pharmaceuticals Inc., H1 2015 215

Prostate Cancer-Pipeline by EndoCeutics, Inc., H1 2015 216

Prostate Cancer-Pipeline by Endocyte, Inc., H1 2015 217

Prostate Cancer-Pipeline by EntreChem, S.L., H1 2015 218

Prostate Cancer-Pipeline by Errant Gene Therapeutics, LLC, H1 2015 219

Prostate Cancer-Pipeline by Esperance Pharmaceuticals, Inc., H1 2015 220

Prostate Cancer-Pipeline by Evgen Limited, H1 2015 221

Prostate Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 222

Prostate Cancer-Pipeline by Ferring International Center S.A., H1 2015 223

Prostate Cancer-Pipeline by Foresee Pharmaceuticals, LLC, H1 2015 224

Prostate Cancer-Pipeline by Fortress Biotech, Inc., H1 2015 225

Prostate Cancer-Pipeline by Fujifilm Corporation, H1 2015 226

Prostate Cancer-Pipeline by Galectin Therapeutics, Inc., H1 2015 227

Prostate Cancer-Pipeline by Galileo Research s.r.l., H1 2015 228

Prostate Cancer-Pipeline by Genelux Corporation, H1 2015 229

Prostate Cancer-Pipeline by Genentech, Inc., H1 2015 230

Prostate Cancer-Pipeline by Genmab A/S, H1 2015 231

Prostate Cancer-Pipeline by GenSpera, Inc., H1 2015 232

Prostate Cancer-Pipeline by Glactone Pharma AB, H1 2015 233

Prostate Cancer-Pipeline by GlaxoSmithKline Plc, H1 2015 234

Prostate Cancer-Pipeline by GlycoMimetics, Inc., H1 2015 235

Prostate Cancer-Pipeline by GP Pharm, S.A., H1 2015 236

List of Figures

Number of Products under Development for Prostate Cancer, H1 2015 64

Number of Products under Development for Prostate Cancer-Comparative Analysis, H1 2015 65

Number of Products under Development by Companies, H1 2015 66

Number of Products under Investigation by Universities/Institutes, H1 2015 87

Comparative Analysis by Late Stage Development, H1 2015 93

Comparative Analysis by Clinical Stage Development, H1 2015 94

Comparative Analysis by Early Stage Products, H1 2015 95

Assessment by Monotherapy Products, H1 2015 362

Assessment by Combination Products, H1 2015 363

Number of Products by Top 10 Targets, H1 2015 364

Number of Products by Stage and Top 10 Targets, H1 2015 364

Number of Products by Top 10 Mechanism of Actions, H1 2015 382

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 382

Number of Products by Top 10 Routes of Administration, H1 2015 396

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 396

Number of Products by Top 10 Molecule Types, H1 2015 398

Number of Products by Stage and Top 10 Molecule Types, H1 2015 398

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

A. Menarini Industrie Farmaceutiche Riunite Srl

AB Science

AbbVie Inc.

Acino Pharma AG

Actinium Pharmaceuticals, Inc.

Adamis Pharmaceuticals Corporation

ADC Therapeutics Sarl

Addex Therapeutics Ltd

Aduro BioTech, Inc.

Advanced Cancer Therapeutics

Advantagene, Inc.

Advaxis, Inc.

Aeterna Zentaris Inc.

Aileron Therapeutics, Inc.

Akshaya Bio Inc.

Alchemia Limited

Alethia Biotherapeutics Inc.

Almac Discovery Limited

Ambrx, Inc.

Amgen Inc.

Amorfix Life Sciences Ltd.

Anavex Life Sciences Corp.

AndroScience Corporation

Angion Biomedica Corp.

AntiCancer, Inc.

Antigen Express, Inc.

Antisense Therapeutics Limited

Aphios Corporation

APIM Therapeutics AS

Aptose Biosciences Inc.

Armour Therapeutics Inc.

Arno Therapeutics, Inc.

ArQule, Inc.

Arrien Pharmaceuticals, LLC

Arrowhead Research Corporation

Ascenta Therapeutics, Inc.

Astellas Pharma Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca Plc

ATLAB Pharma SAS

Avipep Pty Ltd

Axelar AB

Azaya Therapeutics Incorporated

Bavarian Nordic A/S

Bayer AG

Bellicum Pharmaceuticals, Inc.

Beta Pharma, Inc.

BHR Pharma, LLC

BIND Therapeutics, Inc.

Bio-Cancer Treatment International Limited

Bio-Path Holdings, Inc.

BioMarin Pharmaceutical Inc.

Bionature E.A. Ltd.

Bionomics Limited

Biotest AG

Biscayne Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Camurus AB

Celgene Corporation

CellCentric Ltd

Celldex Therapeutics, Inc.

Cellectar Biosciences, Inc.

Champions Oncology, Inc.

Cimab S.A.

Colby Pharmaceutical Company

Cold Genesys, Inc.

Corcept Therapeutics Incorporated

Crescendo Biologics Limited

CureTech Ltd.

CureVac GmbH

CytoVac A/S

CZ BioMed Corp

Daiichi Sankyo Company, Limited

DEKK-TEC, Inc.

DexTech Medical AB

DiaMedica Inc.

DormaTarg, Inc.

Eisai Co., Ltd.

Eli Lilly and Company

Emergent BioSolutions Inc.

Enceladus Pharmaceuticals BV

Endo Pharmaceuticals Inc.

EndoCeutics, Inc.

Endocyte, Inc.

EntreChem, S.L.

Errant Gene Therapeutics, LLC

Esperance Pharmaceuticals, Inc.

Evgen Limited

F. Hoffmann-La Roche Ltd.

Ferring International Center S.A.

Foresee Pharmaceuticals, LLC

Fortress Biotech, Inc.

Fujifilm Corporation

Galectin Therapeutics, Inc.

Galileo Research s.r.l.

Genelux Corporation

Genentech, Inc.

Genmab A/S

GenSpera, Inc.

Glactone Pharma AB

GlaxoSmithKline Plc

GlycoMimetics, Inc.

GP Pharm, S.A.

GTx, Inc.

Humanetics Corporation

Hybrigenics S.A.

IC-MedTech, Inc.

IGF Oncology, LLC.

Ignyta, Inc.

Ildong Pharmaceutical Co., Ltd.

Immunocore Limited

ImmunoFrontier, Inc.

Immunomedics, Inc.

Immunovaccine, Inc.

Innate Immunotherapeutics Limited

Inovio Pharmaceuticals, Inc.

Io Therapeutics, Inc.

Ipsen S.A.

IRX Therapeutics, Inc.

Isis Pharmaceuticals, Inc.

Johnson & Johnson

Kadmon Corporation, LLC

Kancera AB

Karyopharm Therapeutics, Inc.

Komipharm International Co., Ltd.

Kyowa Hakko Kirin Co., Ltd.

Lidds AB

Luye Pharma Group Ltd.

MacroGenics, Inc.

Mebiopharm Co., Ltd.

Medeia Therapeutics Ltd.

MediaPharma s.r.l.

MediGene AG

MedImmune, LLC

Mediolanum farmaceutici S.p.A.

Medivation, Inc.

MEI Pharma, Inc.

Merck & Co., Inc.

Merck KGaA

Merrion Pharmaceuticals Plc

Millennium Pharmaceuticals, Inc.

Mirna Therapeutics, Inc.

MolMed S.p.A.

Morphotek, Inc.

Nanobiotix

Natco Pharma Limited

NewLink Genetics Corporation

Novartis AG

Novogen Limited

Nymox Pharmaceutical Corporation

Oasmia Pharmaceutical AB

Omeros Corporation

Omnitura Therapeutics Inc.

Oncbiomune, L.L.C.

Oncodrone BV

Oncogenex Pharmaceuticals, Inc.

Oncology Research International Limited

Oncolytics Biotech Inc.

OncoMax

OncoNOx ApS

Oncothyreon Inc.

Oncovir, Inc.

OncoVista Innovative Therapies, Inc.

Onyx Pharmaceuticals, Inc.

ORCA Therapeutics B.V.

Orion Oyj

Orphagen Pharmaceuticals, Inc.

Otsuka Holdings Co., Ltd.

OXiGENE, Inc.

Panacela Labs, Inc.

Pantarhei Bioscience BV

Pfizer Inc.

Pharmedartis GmbH

Pharmicell Co., Ltd.

Pharminox Limited

Philogen S.p.A.

Polaris Pharmaceuticals, Inc.

Polyplus-transfection SA

Prima BioMed Ltd.

Progenics Pharmaceuticals, Inc.

ProMetic Life Sciences Inc.

Provenance Biopharmaceuticals Corp.

PSites Pharma GmbH

Qu Biologics Inc.

Quest PharmaTech Inc.

RedHill Biopharma Ltd.

RestorGenex Corporation

Rexahn Pharmaceuticals, Inc.

Rigontec GmbH

Sanofi

Sareum Holdings Plc

SEEK Group

Serometrix, LLC

Shenogen Pharma Group Ltd.

Solasia Pharma K.K.

Sophiris Bio, Inc.

Soricimed Biopharma Inc.

Sotio a.s.

Sun Pharma Advanced Research Company Ltd.

Sunesis Pharmaceuticals, Inc.

Supratek Pharma Inc.

Synta Pharmaceuticals Corp.

Tactic Pharma, LLC

Takeda Pharmaceutical Company Limited

Teikoku Pharma USA, Inc.

Teva Pharmaceutical Industries Limited

Theravectys S.A.

TheRyte Limited

Tokai Pharmaceuticals, Inc.

Tolero Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc.

Treat U, S.A.

TVAX Biomedical, Inc.

Ultimovacs AS

Vaccibody AS

ValiRx Plc

Vasgen Limited

Vaxeal Holding SA

Vaxon Biotech

Vicore Pharma AB

Vicus Therapeutics, LLC

Viralytics Ltd.

ViraTherapeutics GmbH

Viventia Biotechnologies Inc.

vTv Therapeutics Inc.

WntResearch AB

Zensun (Shanghai) Sci & Tech Co., Ltd.

Zymeworks Inc.

Prostate Cancer Therapeutic Products under Development, Key Players in Prostate Cancer Therapeutics, Prostate Cancer Pipeline Overview, Prostate Cancer Pipeline, Prostate Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com